MAP2K1 and metastatic melanoma: In this study, through analysis of the sequencing and survival data for several public cohorts with metastatic melanoma, we investigated the association between MAP2K1/2 mutations and the response to anti-CLTA-4 and anti-PD-1 immunotherapies.